Jump to Navigation

Facebook Connect

User login

2014 Statin Safety Update

The National Lipid Association Addresses the Safety of Statins and Provides Recommendations to Clinicians and Patients

The National Lipid Association (NLA) recently convened an Expert Panel on Statin Safety to examine various aspects of statin therapy and to determine its safety, patient tolerance and effectiveness. Results of the symposium findings are published this month in the Journal of Clinical Lipidology, addressing six specific statin-related safety issues including the effects of statins on: cognition, diabetes risk, liver function, muscle symptoms, interactions with other drugs, and statin intolerance.

Clinicians

The NLA convened an expert panel on Statin Safety to address six specific statin-related safety issues including the effects of statins on: cognition, diabetes risk, liver function, muscle symptoms, interactions with other drugs, and statin intolerance. The paper reflects an update of a consensus report that was published by the NLA in 2006 related to the muscle, liver, renal and neurologic effects of statins.

To view highlight slides of the statin safety paper, click here.

To read the complete paper, visit us at the Journal of Clinical Lipidology Online (This paper will be accessible to everyone through May 4, 2014. After that date, abstracts will continue to be available to the general public. NLA Members and Journal Subscribers can login here).

Patients

With an estimated 15 million Americans taking a statin drug to reduce high cholesterol, patients and health care providers alike are seeking more information on the pros and cons of statin therapy.

The NLA Statin Safety Panel recognized that in starting any new drug the potential benefits must be weighed against the potential risks, and that “the initiation of statins was heavily weighted to overwhelmingly benefit those at increased cardiovascular risk.”

As always, you should consult with your health care provider regarding your individual needs and before taking any medications.

To view the news release on the Statin Safety Panel report, go here.

 

Media

  • News release: The National Lipid Association Addresses the Safety of Statins and Provides Recommendations to Clinicians and Patients. Click here to view
  • To view highlight slides of the statin safety paper, click here.

    To read the complete paper, visit us at the Journal of Clinical Lipidology Online (This paper will be accessible to everyone through May 4, 2014. After that date, abstracts will continue to be available to the general public. NLA Members and Journal Subscribers can login here).

  • Media queries contact Judi Spann, communications@lipid.org  904-998-0854
Original Posting Date: 
Tuesday, April 22, 2014 - 13:00
Rating: 
0
No votes yet



by Dr. Radut.